Compare Enveric Biosciences Inc (ENVB) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Banco Santander SA — how do they compare? Enveric Biosciences Inc trades at $1.43 (market cap $5.32M), while Banco Santander SA trades at $13.69 (market cap $195.14B). The key difference: Banco Santander SA is far larger — about 36680.5× Enveric Biosciences Inc's market cap, and Banco Santander SA pays a 2.01% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | SAN | |
|---|---|---|
Market Cap | $5.32M | $195.14B |
Sector | Health | Financials |
52-Week High | $17.40 | $14.37 |
52-Week Low | $1.28 | $8.40 |
Enterprise Value | $408.82K | — |
Dividend Yield | — | 2.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.41, up 6.82% in the last session. The stock shows a bearish technical trend with moving averages signaling sell, but oscillators are neutral. Financially, the company reported a net loss of $8.77M for 2025, with negative ROE and ROA, though it consistently beat EPS expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003.
Outlook is speculative with high risk due to negative profitability and cash burn, offset by strong analyst buy ratings (75%) and positive clinical updates. Key risks include funding needs and drug development hurdles, while catalysts hinge on regulatory milestones and partnership news.
SAN trades at $13.67, up 0.29% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported Q1 2026 EPS of $0.4144, beating expectations of $0.29, and maintains a strong net income margin of 26.72%. Recent developments include the acquisition of TSB and AI-driven efficiency initiatives targeting over $1.15 billion in business value.
Outlook is positive with analyst consensus at 64% buy ratings, supported by record profitability and a dividend yield from the recent $0.15 payout. Risks include declining operating cash flow, high debt levels, and antitrust probes in Spain. The stock offers value with a P/E of 13.73 and ROE of 16.18%, but investors should monitor cash flow trends and regulatory outcomes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
